Notch 塑造乳腺癌的先天免疫表型
该研究在小鼠自发乳腺癌模型和人乳腺癌表达谱中显示,肿瘤细胞 Notch 激活可调控 IL1β 与 CCL2 表达及肿瘤相关巨噬细胞募集,并参与巨噬细胞对肿瘤细胞 TGFβ 介导的激活,形成 Notch 依赖的旁分泌环路;表达谱分析显示 Notch 激活、IL1β 与 CCL2 产生、巨噬细胞浸润与基底样乳腺癌(BLBC)显著相关。作者认为这些发现为 Notch 激活的 BLBC 提供了免疫治疗机会。
要点
- 肿瘤细胞 Notch 调控 IL1β 和 CCL2 表达及肿瘤相关巨噬细胞募集。
- Notch 参与巨噬细胞对肿瘤细胞 TGFβ 介导的激活,形成旁分泌环路。
- 表达谱分析显示 Notch 激活、IL1β 与 CCL2 产生、巨噬细胞浸润与 BLBC 显著相关。
核心结论
- 作者认为 Notch 处于巨噬细胞浸润与细胞因子分泌放大的恶性循环核心,并为 BLBC 提供免疫治疗机会。
研究设计与样本
- 研究使用可在自发乳腺癌中调控 Notch 的小鼠模型,并结合人乳腺癌表达谱分析。
主要发现
- 肿瘤细胞 Notch 调控 IL1β 和 CCL2 表达及肿瘤相关巨噬细胞募集。
- Notch 调控肿瘤相关巨噬细胞对肿瘤细胞 TGFβ 介导的激活,形成 Notch 依赖的旁分泌信号环路。
- 小鼠自发乳腺癌模型中 IL1β 和 CCL2 产生及巨噬细胞募集为 Notch 依赖。
- 人乳腺癌表达谱分析显示 Notch 激活、IL1β 与 CCL2 产生、巨噬细胞浸润与 BLBC 显著相关。
关键数值与推荐
- 原文未报告具体效应量、阈值或统计学数值。
临床怎么用
- 作者指出 IL1β 和 CCL2 拮抗剂目前正处于治疗良性炎症性疾病的临床评审中,其向肿瘤临床转化可能产生快速影响。
- 原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Notch activation, which is associated with basal-like breast cancer (BLBC), normally directs tissue patterning, suggesting that it may shape the tumor microenvironment. Here, we show that Notch in tumor cells regulates the expression of two powerful proinflammatory cytokines, IL1β and CCL2, and the recruitment of tumor-associated macrophages (TAM). Notch also regulates TGFβ-mediated activation of tumor cells by TAMs, closing a Notch-dependent paracrine signaling loop between these two cell types. We use a mouse model in which Notch can be regulated in spontaneous mammary carcinoma to confirm that IL1β and CCL2 production, and macrophage recruitment are Notch-dependent. In human disease, expression array analyses demonstrate a striking association between Notch activation, IL1β and CCL2 production, macrophage infiltration, and BLBC. These findings place Notch at the nexus of a vicious cycle of macrophage infiltration and amplified cytokine secretion and provide immunotherapeutic opportunities in BLBC.Significance: BLBC is aggressive and has an unmet need for effective targeted treatment. Our data highlight immunotherapeutic opportunities in Notch-activated BLBC. Effective IL1β and CCL2 antagonists are currently in clinical review to treat benign inflammatory disease, and their transition to the cancer clinic could have a rapid impact. Cancer Discov; 7(11); 1320-35. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 1201.
引用
- Shen Q, Cohen B, Zheng W, et al. Notch Shapes the Innate Immunophenotype in Breast Cancer. Cancer Discov. 2017. PMID: 28790030. doi:10.1158/2159-8290.CD-17-0037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。